Insider Transactions in Q2 2025 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 23
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,926
-1.92%
|
$21,186
$11.31 P/Share
|
|
May 23
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,146
-1.86%
|
$23,606
$11.31 P/Share
|
|
May 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,125
+3.03%
|
-
|
|
May 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+4.16%
|
-
|
|
May 22
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
9,999
-3.16%
|
$109,989
$11.88 P/Share
|
|
May 22
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,317
-2.33%
|
$25,487
$11.88 P/Share
|
|
May 22
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,689
-2.38%
|
$29,579
$11.88 P/Share
|
|
May 21
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
23,250
+6.84%
|
-
|
|
May 21
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+3.64%
|
-
|
|
May 21
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+5.25%
|
-
|
|
May 19
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,776
-2.54%
|
$30,536
$11.84 P/Share
|
|
May 19
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
3,808
-1.28%
|
$41,888
$11.84 P/Share
|
|
May 19
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,600
-2.65%
|
$28,600
$11.84 P/Share
|
|
May 17
2025
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
6,447
+5.57%
|
-
|
|
May 17
2025
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
9,364
+3.05%
|
-
|
|
May 17
2025
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,205
+4.11%
|
-
|
|
Apr 09
2025
|
Venrock Healthcare Capital Partners Iii, L.P. |
BUY
Open market or private purchase
|
Indirect |
25,000
+0.47%
|
$225,000
$9.42 P/Share
|